{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:29:14Z","timestamp":1770708554730,"version":"3.49.0"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology subsidy from the Ministry of Science and Higher Education"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Cancer of unknown primary represents 3\u20135% of all cancer cases. This study aimed to identify the clinical and pathological factors affecting survival in these patients before the introduction of next-generation sequencing in modern molecular diagnostics. Methods: A retrospective cross-sectional observational study involving 149 patients with CUP at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, was conducted between 2006 and 2016. Clinical records were analyzed to gather demographic, clinical, and pathological data. Statistical analyses, including the Kaplan\u2014Meier method, estimated overall survival (OS), and Cox proportional hazards modeling, were used to identify significant clinical factors associated with survival. Results: The mean age was 59 years, and 57% of the patients were male. Most patients (59.44%) had an ECOG of 0\u20131. The most common metastatic sites were the lymph nodes (63.64%), liver (41.26%), bones (23.78) and lungs (21.68%). The median overall survival for the cohort was 7.1 months, with notable survival disparities based on several clinical and laboratory factors. Multivariate analysis revealed that ECOG score &gt;1 (HR = 1.69, 95% CI: 1.10\u20132.60, p = 0.016), elevated ALP (HR = 1.81, 95% CI: 1.20\u20132.74, p = 0.005), elevated calcium level (HR = 2.08, 95% CI: 1.05\u20134.13, p = 0.037), and NLR \u22652.61 (HR = 2.55, 95% CI: 1.67\u20133.89, p &lt; 0.001) were independent predictors of poorer survival. Elevated LDH showed a consistent trend toward poorer survival but did not reach significance in the fully adjusted model (HR = 1.50, 95% CI: 0.99\u20132.27, p = 0.054). Conclusions: This study provides insights into the survival and prognostic factors influencing CUP patients, assisting clinicians in treatment eligibility assessments and guiding future investigations.<\/jats:p>","DOI":"10.3390\/cancers18040565","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:42:42Z","timestamp":1770640962000},"page":"565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ten-Year Experience in the Treatment of Cancers of Unknown Primary from Poland: From Overall Survival to Factors Influencing Response in the Prepersonalization Era"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-8005","authenticated-orcid":false,"given":"Konrad","family":"Ta\u0142asiewicz","sequence":"first","affiliation":[{"name":"Department of Oncology Diagnostics and Palliative Medicine, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (MSCI), Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Czachowska","sequence":"additional","affiliation":[{"name":"Department of Oncology Diagnostics and Palliative Medicine, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (MSCI), Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-1689","authenticated-orcid":false,"given":"Marcin","family":"Folwarski","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition and Dietetics, Medical University of Gda\u0144sk, D\u0119binki 7, 80-211 Gda\u0144sk, Poland"},{"name":"Nicolaus Copernicus Hospital, Nowe Ogrody 1-6, 80-803 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[{"name":"Center of Excellence in Precision Oncology, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (MSCI), Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Jaxa-Larecka","sequence":"additional","affiliation":[{"name":"Department of Oncology Diagnostics and Palliative Medicine, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (MSCI), Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-6641","authenticated-orcid":false,"given":"Aleksandra","family":"Kapa\u0142a","sequence":"additional","affiliation":[{"name":"Department of Oncology Diagnostics and Palliative Medicine, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (MSCI), Roentgena 5, 02-781 Warsaw, Poland"},{"name":"Department of Clinical Nutrition, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (MSCI), Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","article-title":"The currently declining incidence of cancer of unknown primary","volume":"61","author":"Rassy","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5603\/njo.99065","article-title":"Cancer incidence and mortality in Poland in 2023","volume":"74","author":"Didkowska","year":"2024","journal-title":"Nowotw. J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1002\/cam4.1689","article-title":"Cancer of unknown primary\u2014Epidemiological trends and relevance of comprehensive genomic profiling","volume":"7","author":"Binder","year":"2018","journal-title":"Cancer Med."},{"key":"ref_4","first-page":"228","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Bochtler","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1200\/JCO.2002.04.019","article-title":"Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site","volume":"20","author":"Culine","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejca.2012.01.011","article-title":"Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial","volume":"48","author":"Fourcade","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604818","article-title":"Paclitaxel and carboplatin vs. gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: A randomised prospective phase II trial","volume":"100","author":"Huebner","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bjc.2012.516","article-title":"Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: A systematic review and meta-analysis","volume":"108","author":"Lee","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","article-title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: A phase II trial","volume":"14","author":"Pouyiourou","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e004822","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): A phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_13","unstructured":"(2025, January 14). Orphanet: Cancer of Unknown Primary Site. Available online: https:\/\/www.orpha.net\/en\/disease\/detail\/631251."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): An open-label, randomised, phase 2 study","volume":"404","author":"Bochtler","year":"2024","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canep.2014.03.010","article-title":"Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961\u20132010","volume":"38","author":"Brewster","year":"2014","journal-title":"Cancer Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.22300","article-title":"Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site","volume":"107","author":"Seve","year":"2006","journal-title":"Cancer"},{"key":"ref_17","first-page":"481","article-title":"Patients with Cancer of Unknown Primary","volume":"111","author":"Puthenparambil","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/ijc.32882","article-title":"Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary","volume":"146","author":"Bochtler","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-20-4117","article-title":"Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary","volume":"27","author":"Raghav","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PPO.0b013e3181c6aa89","article-title":"Paclitaxel\/Carboplatin\/Etoposide Versus Gemcitabine\/Irinotecan in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site","volume":"16","author":"Hainsworth","year":"2010","journal-title":"Cancer J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ctrv.2009.05.005","article-title":"Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis","volume":"35","author":"Golfinopoulos","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","article-title":"Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study\u2014Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)","volume":"21","author":"Culine","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases","volume":"5","author":"Gatalica","year":"2014","journal-title":"Oncotarget"},{"key":"ref_25","first-page":"v851","article-title":"Randomised Efficacy and Safety Results for Atezolizumab (Atezo) + Bevacizumab (Bev) in Patients (pts) with Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115447","DOI":"10.1016\/j.ejca.2025.115447","article-title":"Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis","volume":"222","author":"Labaki","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): A randomised controlled trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_30","first-page":"101524","article-title":"Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: A retrospective analysis","volume":"60","author":"Dupain","year":"2025","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Brlek, P., Buli\u0107, L., Shah, N., Shah, P., and Primorac, D. (2025). In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062568"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"i75","DOI":"10.1093\/annonc\/mdi804","article-title":"ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)","volume":"16","author":"Briasoulis","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ii106","DOI":"10.1093\/annonc\/mdn104","article-title":"Cancers of unknown primary site: ESMO Clinical Recommendation for diagnosis, treatment and follow-up","volume":"19","author":"Briasoulis","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"vi64","DOI":"10.1093\/annonc\/mdr389","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Fizazi","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/bjc.1998.395","article-title":"A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)","volume":"77","author":"Warner","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/02841860701843043","article-title":"Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study","volume":"47","author":"Pentheroudakis","year":"2008","journal-title":"Acta Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2135","DOI":"10.1097\/MD.0000000000002135","article-title":"A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin","volume":"94","author":"Huang","year":"2015","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ctrv.2013.03.001","article-title":"Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature","volume":"39","author":"Petrakis","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO.1995.13.7.1720","article-title":"Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site","volume":"13","author":"Verweij","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12094-007-0084-6","article-title":"Carcinoma of unknown primary site: Development in a single institution of a prognostic model based on clinical and serum variables","volume":"9","author":"Lorenzo","year":"2007","journal-title":"Clin. Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1200\/JCO.1994.12.6.1272","article-title":"Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients","volume":"12","author":"Abbruzzese","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1200\/JCO.1997.15.5.2056","article-title":"Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma?","volume":"15","author":"Lenzi","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","article-title":"Survival in cancer of unknown primary site: Population-based analysis by site and histology","volume":"23","author":"Hemminki","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/bjc.2013.683","article-title":"Inflammation as a validated prognostic determinant in carcinoma of unknown primary site","volume":"110","author":"Mohamed","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5114\/wo.2025.147939","article-title":"Cancer, malnutrition and inflammatory biomarkers. Why do some cancer patients lose more weight than others?","volume":"29","author":"Grochowska","year":"2025","journal-title":"Wspolczesna Onkol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2000011","DOI":"10.1002\/ardp.202000011","article-title":"Recent advances with alkaline phosphatase isoenzymes and their inhibitors","volume":"353","author":"Zaher","year":"2020","journal-title":"Arch. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.21037\/tcr-23-1190","article-title":"Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?","volume":"12","author":"Jiang","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Forget, P., Khalifa, C., Defour, J.-P., Latinne, D., Van Pel, M.-C., and De Kock, M. (2017). What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res. Notes, 10.","DOI":"10.1186\/s13104-016-2335-5"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Cupp, M.A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., and Berlanga-Taylor, A.J. (2020). Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med., 18.","DOI":"10.1186\/s12916-020-01817-1"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41416-018-0231-6","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases","volume":"119","author":"Thio","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12032-014-0305-0","article-title":"The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients","volume":"31","author":"Ying","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e074874","DOI":"10.1136\/bmjopen-2023-074874","article-title":"Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis","volume":"13","author":"Qi","year":"2023","journal-title":"BMJ Open"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhou, X., Du, Y., Huang, Z., Xu, J., Qiu, T., Wang, J., Wang, T., Zhu, W., and Liu, P. (2014). Prognostic Value of PLR in Various Cancers: A Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101119"},{"key":"ref_54","first-page":"67","article-title":"Hypercalcemia of malignancy--new insights into an old syndrome","volume":"47","author":"Esbrit","year":"2001","journal-title":"Clin. Lab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JGO.2016.006890","article-title":"Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes","volume":"3","author":"Ramos","year":"2017","journal-title":"J. Glob. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:07:16Z","timestamp":1770642436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040565"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040565","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}